cyrilzakka/clinical-trials huggingface dataset:
Hallux Valgus Manual Therapy Based on Global Postural Reeducation.

Manual approach of Hallux Valgus with global postural reeducation.

Hallux Abducto Valgus is a frequent pathology with a prevalence of 30% in women and 13% in men. The tendency is to increase with age.

Usually, the elected treatment is surgery, as the conservative orthopedic methods are used at the early stages of the pathology. Global Postural Re-Education is a manual therapy treatment method through which we can treat lots of pathologies. Some investigations demonstrate Postural Re-Education is effective for the treatment of temporomandibular disorders, urinary incontinence, and spine disorders, but there is no scientific evidence that defends the improvement of the symptoms and correction of the angle of the Hallux Abducto Valgus using Postural Re-Education.

Eligibility Criteria:
Inclusion Criteria:

* hallux abducto valgus with an angle between 15 - 39º
* pain on the medial or plantar face of the forefoot
* Physical independence to take part in the study.

Exclusion Criteria:

* Being under hallux abducto valgus treatment.
* Lower limb surgery.
* Fracture or disfunction on the lower limb other than hallux valgus which may affect the studied variables.
Stroke Treatment With Acute Reperfusion and Simvastatin

The purpose of this study is to determine whether simvastatin treatment started within the first 12 hours from stroke onset improves neurological and functional outcomes, evaluated at seventh day/discharge or at the third month.

Also, to demonstrate that simvastatin is safe and not associated with higher rates of hemorrhagic transformation in patients who receive thrombolysis.


Eligibility Criteria:
Inclusion Criteria:

* Patients older than 18 years acute ischemic stroke (less than 12 hours from stroke onset).
* Stroke involving MCA-ACA-PCA.
* NIHSS score 4 to 22.
* Previous modified Rankin Scale score of 1 or 0.
* Patient or proxy informed consent.
* Patients not taking statins for the past six months.

Exclusion Criteria:

* Pregnancy or breastfeeding.
* Clinical or radiological evidence on admission of intracranial hemorrhage, hemorrhagic infarction or tumor.
* Seizures at the time of inclusion.
* Complete or substantial recovery prior to randomization.
* Patients with ipsilateral neurological deficit that may mask the evaluation of the current event.
* Liver disease (AST or ALT more than twice upper normality limit).
* Cardiogenic shock or relevant cardiac failure.
* Patients with more than five times upper normality limit of CPK.
* Myocardial infarction or any other thromboembolic event within the previous 30 days.
* Active infection by the time of inclusion.
* Documented hypersensibility to statins.
* Drug abuse.
* Expected short life-expectancy related to other systemic diseases.
The Effect of CQI on the Outcome of Patients Supported With ECMO

This was a prospective observational study in comparison with a retrospective control group(Jan 2015 to Jun 2019). Two ICUs in China were included. The continuous quality improvement (CQI)strategies were implemented from Jul 2019 to Jun 2021(CQI group). The mortalities of ECMO patients was compared between the CQI group and the control group.


Eligibility Criteria:
Inclusion Criteria:

* Patients over 18 years old who received ECMO support in the centers

Exclusion Criteria:

* patients waiting for transplantation with ECMO.
Simvastatin Versus MTA in Pulpotomy of Immature Permanent Molars

the study will be done to evaluate the clinical and digital radiographic success of simvastatin versus MTA in pulpotomy of immature permanent molars

the clinical and digital radiographic success of simvastatin versus MTA in pulpotomy of immature permanent molars for the following patients which include: Healthy children aged from 6 to 8 years who will be classified as Class I or II Children according to the American Society of Anaesthesiologists (ASA) will be included. Children with severe behavioral, or emotional disabilities, and medically compromised children will be excluded.

Eligibility Criteria:
Inclusion Criteria:

* Healthy children aged from 6 to 8 years
* Children with severe behavioral, or emotional disabilities, and medically compromised children will be excluded.
* Deep carious lesions of the first permanent immature molars with signs \& symptoms of reversible pulpitis will be included
* Normal radiographic findings and immature roots
Covid-19 Epidemic on Acute Stroke Management

The Covid-19 pandemic is a pandemic of an emerging infectious disease, coronavirus 2019 (Covid-19), caused by the coronavirus SARS-CoV-2. It appears in November 2019 in the city of Wuhan, China, and spreads worldwide from February 2020. The first cases of infection in France were confirmed on 24 January 2020. As of April 14, 103,573 cases of infection were confirmed, 32,292 hospitalized cases, including 6,730 in intensive care, with 15,729 deaths recorded1. The most affected regions are Ile de France and the Grand Est (in particular the Haut-Rhin department). Containment of the entire French population was introduced on 17 March, with the aim of reducing the spread of the virus and relieving the burden on the health system, particularly the intensive care units.

This unprecedented health crisis, as well as the social containment measures in themselves, has repercussions on other acute medical pthologies, not directly related to the viral infection. It appears that the number of patients treated for acute stroke has suddenly declined since the beginning of the epidemic.

However, it is not clear whether it is the incidence of stroke that has declined or simply the proportion of patients presenting within the time frame that allows for treatment in the acute phase (by thrombolysis or thrombectomy).


Eligibility Criteria:
Inclusion Criteria:

* Adult patient
* Stroke Patients
* Patient who agreed to participate in this study

Exclusion Criteria:

- Refusal to participate in this study
Virtual Reality and Subjective Tinnitus

The purpose of this study is to test if virtual reality immersion has the potential to significantly decrease subjective tinnitus intrusiveness when compared to standard care.

This is a randomised controlled study aimed at further validating the use of Virtual Reality in the field of subjective tinnitus management. Indeed, earlier results have suggested that this innovative strategy has the potential to be as efficient as a Cognitive and Behavioural Therapy.

Before the sessions, an automated tinnitus matching procedure will help create a sound similar to the tinnitus percept ("Tinnitus Avatar").

During the sessions (8 sessions; 30 minutes), the "Tinnitus Avatar" will be displayed auditorily but also visually - as a sparkling spot - in a variety of virtual 3D auditory and visual environments.

In these virtual environments the patients will be given the possibility to voluntarily control and manipulate the "Tinnitus Avatar" by the means of a wand on top of which the sound and the sparkling will be attached. They will also be able to freely navigate in the virtual scenes where environmental sound will be displayed.

Then the patients will be able to displace at will the "Tinnitus Avatar" in their peri-personal space or mask it by getting close to sounds they may encounter in the virtual scenes.

It is supposed that regaining and training a capacity of interaction with the "Tinnitus Avatar" as if it were a standard sound will help recalibrate the attentional processes involved in tinnitus perception and then to decrease tinnitus intrusiveness.

Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years and \< 75 years,
* French speaking and ability to understand multidimensional questionnaires,
* Subjective tinnitus of peripheral origin (middle or inner ear auditory nerve)
* Subjective tinnitus stable and chronic (lasting for more than 6 months)
* Subjective tinnitus that can be characterized by tinnitus matching
* Normal hearing or moderate hearing loss

Exclusion Criteria:

* Fluctuating tinnitus,
* Unilateral or bilateral severe or profound hearing loss,
* Claustrophobia, visual, impairment, vertigo or dizziness, chronic headache or any other condition contraindicating virtual immersion
* Psychiatric condition requiring immediate management
* Pregnant or breastfeeding women
* Protected adults (including individual under guardianship by court order)
* Persons deprived of their liberty by judicial or administrative decision
A Pilot Evaluation of Adhesives and How They Are Impacted by Output

The study investigates the impact real output has on the adhesion of adhesives.


Eligibility Criteria:
Inclusion Criteria:

1. Have given written informed consent
2. Be at least 18 years of age and have full legal capacity
3. Have had an ileostomy for more than one year
4. Have intact skin on the area used in the evaluation
5. Has an ileostomy with a diameter up to (≤) 35 mm
6. Have a peristomal area accessible for application of patches/adhesive strips (assessed by investigating scientist)

Exclusion Criteria:

1. Currently receiving or have within the past 2 month received radio- and/or chemotherapy
2. Currently receiving or have within the past month received topical steroid treatment in the peristomal skin area or systemic steroid (tablet/injection) treatment.
3. Are pregnant or breastfeeding
4. Having dermatological problems in the peristomal- or abdominal area (assessed by investigating scientist)
5. Participating in other interventional clinical investigations or have previously participated in this evaluation
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

This clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) from the thyroid to determine whether the participant has a malignant (cancer) or benign (not showing cancer) thyroid tumor. The information learned from this trial may help develop a more accurate test so that patients do not have unnecessary surgeries for nodules that are thought to be suspicious but are actually benign.

PRIMARY OBJECTIVE:

I. To evaluate the effect of Diagnostic DNA Methylation Signatures (DDMS-2) results (positive predictive value \[PPV\], negative predictive value \[NPV\], sensitivity and specificity) on physician decision-making for clinical management of 800 indeterminate thyroid nodules.

SECONDARY OBJECTIVES:

I. To determine sensitivity and specificity, PPV, NPV of DDMS-2 with 1450 needle biopsies including 800 needle biopsies with indeterminate cytopathology.

II. Compare the diagnostic accuracy between DDMS-2 and two currently used diagnostic approaches based on genetic alterations and gene expression within the same prospective cohort of 800 indeterminate needle biopsies.

OUTLINE:

Patients undergo needle biopsy for collection of tissue samples. Tissue samples are analyzed using DDMS-2. Patients' medical records are also reviewed.

Eligibility Criteria:
Inclusion Criteria:

* Patients without impaired decision-making capacity and who are undergoing needle biopsies for thyroid nodule diagnosis
* Over the age of 18
* Any gender, race and ethnicity
* Patients must provide informed consent prior to use of their tissues and clinical data

Exclusion Criteria:

* Children are excluded from the study, since the biology of children thyroid nodules is different from adults
Preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery

Thromboembolism is an important perioperative complication in major thoracic surgery, even though current guidelines have recommended postoperative administration of heparin or LMWH for thromboprophylaxis for those high-risk patients, there are still many cases of thromboembolism. Therefore, as the guideline itself writes, the investigators believe the rational of dose and timing of heparin in thoracic surgery are still not well established. Therefore, the investigators aimed to conduct this randomized controlled study to explore the safety and efficacy of preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery.


Eligibility Criteria:
Inclusion Criteria:

* 18-75 years old without any preoperative VTEs;
* patients undergoing major thoracic surgery (including lobectomy, esophagectomy, and thymectomy).

Exclusion Criteria:

* patients with coagulation disorders: preoperative international normalized ratio (INR) \> 1.5, or blood platelet count \< 50x10\^9/L;
* patients receiving any therapeutic anticoagulation preoperatively;
* patients with severe renal or liver dysfunction.
A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)

A study to assess the safety and efficacy of MK8245 as monotherapy compared to placebo.


Eligibility Criteria:
Inclusion Criteria:

* Have Type 2 Diabetes Mellitus
* 18 to 65 years of age

Exclusion Criteria:

* History of Type 1 Diabetes or ketoacidosis
* Have been treated with lipid lowering medications 4 weeks before starting the study
* Have started on a weight loss program and not in the maintenance phase or have started weight loss medication within the last 12 weeks
* Have had surgery in the last 30 days
* History of active liver disease
* History of coronary heart disease or congestive heart failure
* Have had a stroke or transient ischemic neurological disorder in the past 6 months
* Are Human Immunodeficiency Virus (HIV) Positive
Complications and the Influence of COVID-19 on Myocardial Function and Exercise Capacity

The subject of the study is the impact of COVID-19 on the indicators of myocardial efficiency and exercise capacity. As a result of the observed dependencies, it will be possible to start an appropriate diagnostic procedure early, select personalized treatment and develop a model of cardiological care for people with a history of SARS-CoV-2 infection and improve the quality and extend their life.

About 100 adult patients hospitalized in the Department of Cardiology and Congenital Heart Diseases of Adults who had recovered from COVID-19 will be included in the study. Selected prognostic factors will be analyzed, among others: demographic data of the patient, physical examination, symptoms, co-morbidities, results of selected laboratory tests, lung imaging (X-ray or computed tomography) selected electrocardiographic and echocardiographic data, patient's cooperation with the doctor, treatment applied, parameters in the spiroergometric study, body mass analysis. One year after inclusion in the study, a control hospitalization will be performed. The same factors will be analyzed.

Eligibility Criteria:
Inclusion Criteria:

* Age equal to or older than 18 years
* infection with the SARS-CoV-2 in past medical history
* current hospitalization

Exclusion Criteria:

* severe hypertension;
* unstable angina;
* acute pulmonary embolism;
* decompensated heart failure;
* recent myocardial infarction;
* unstable heart rhythm disturbances;
* acute myocarditis or pericarditis;
* active endocarditis;
* advanced atrioventricular block;
* diagnosis of cardiomyopathy (hypertrophic, dilated, restrictive, peripartum, arrhythmogenic)
* lysosomal storage disorders
* severe hyper- and hypothyroidism
* pregnancy and lactation
* chronic kidney disease (IV, V stadium according to NKF) and dialysis treatment
* documented neoplastic process
* the patient's inability to cooperate and/or provide informed consent to participate in a research
* alcohol and drug abuse
* active autoimmune disease
* treatment using immunosuppressants, cytostatic drugs, glucocorticosteroids, or antiretroviral drugs
* a history of bone marrow transplant or other organ transplant, treatment with blood products within the last 6 months
* active systemic infection
* HBV, HCV or HIV carrier or positive for HbS antigen or antibodies to HCV
* surgery or serious injury within the last month
* patients who did not express their informed consent to participate in the study
Characterisation of the Gut Microbiota in Term Infants After Maternal Supplementation of Probiotics

A monocenter, open label pilot study in pregnant women and their offspring with at least four weeks prenatal and four weeks postnatal maternal intervention with a study product consisting of four different food constituents.

The study will investigate the effect of maternal supplementation with the food constituents on the recovery of the constituents in the maternal and infant feces, the microbiota in both mother and infant and potential transmission routes from mother to infant.

Pregnant women will be recruited at the ordinary midwife visit in gestational week 28. The intervention will begin in gestational week 33+0 to ensure at least four weeks prenatal intervention before expected birth.

The study will be conducted in four phases. First phase is the run-in phase. The second phase is the prenatal intervention period from gestational week 33+0 until birth. Third phase is the postnatal intervention period, from birth until four weeks postnatal. The last phase is a two weeks follow-up period without any intake of the investigational product.

Infant stool samples, as well as maternal breast milk samples, stool and urine samples and samples from vagina will be collected on multiple occasions during the study. In addition, sample from placenta, umbilical cord, umbilical cord blood and amnion fluid will be collected. Mothers will be asked to complete electronic questionnaires daily during the course of the study.

Eligibility Criteria:
Inclusion Criteria

Pregnant women:

1. Enrolled at Aarhus University Hospital
2. Singleton pregnancy
3. Age above 18 years at informed consent
4. Aim to give birth vaginally
5. Aim to breastfeed
6. No use of probiotics (contained in dietary supplements/ food) after written consent.

Infants:

1. Gestational age between 37-42 weeks

Exclusion Criteria:

Pregnant women • Use of immunosuppressant drugs.

Infants:

• None
Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan

This study assessed the efficacy and safety of generic imatinib in patients with chronic myeloid leukemia (CML) in Jordan. It was a multicenter, non-interventional, open-label, prospective study combined with retrospective data collection from files of patients with a diagnosis of Ph+ CML, treated with Cemivil (imatinib), where no visits or intervention(s) additional to the daily practice were performed

Primary objectives

Measure the proportion of Philadelphia chromosome positive (Ph+) CML patients in CP treated with Cemivil who achieve optimal response :

* Complete hematologic response (CHR) at 3 months;
* Minor cytogenetic response (mCyR) at 3 months (Ph+ ≤65%); partial cytogenetic response (PCyR) at 6 months (Ph+ ≤35%), and complete cytogenetic response (CCyR) at 12 months (No Ph+ metaphases);
* Major molecular response (MMR) at 12 months of Cemivil therapy \[a ratio of BCR-ABL1 to ABL1 ≤0.1% on the International Scale\];

Assess the safety and tolerability of Cemivil after one year of treatment, based on:

* Incidence, severity, and relationship of adverse events (AEs) to the study medication;
* Serious AEs;
* AEs leading to permanent treatment discontinuation;
* Clinically relevant changes in laboratory tests (according to laboratory reference ranges).

Number of Subjects evaluated: 91 (N=33 received generic imatinib as first-line therapy "first-line patients". N=58 switched from patented imatinib to generic imatinib "switched patients")

Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years
* Newly diagnosed patients with Ph+ CML in CP; or CML patients who started with Cemivil treatment since its registration in Jordan and who confirmed CHR
* Written informed consent

Exclusion Criteria:

* Age \<18 years
* CML in accelerated phase
* CML in blast crisis
* CML with mutation(s) in the BCR-ABL gene
* Contraindications to the administration of the study drug according to the approved Summary of Product Characteristics (SPC)
A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection

The purpose of this study is to evaluate the safety and efficacy of Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) with sofosbuvir (SOF) with or without ribavirin (RBV) in adults with Genotype 2 Chronic Hepatitis C Virus (HCV) infection or Genotype 3 HCV infection with or without Cirrhosis.


Eligibility Criteria:
Inclusion Criteria:

1. Chronic HCV infection prior to study enrollment.
2. Screening laboratory results from the central clinical laboratory indicating HCV genotype 2 or 3 infection only (no mixed genotype).
3. Absence OR presence of cirrhosis.
4. If cirrhotic, need to have compensated cirrhosis and absence of hepatocellular carcinoma (HCC)

Exclusion Criteria:

1. Positive screen for hepatitis B surface antigen or anti-human immunodeficiency virus antibody
2. Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse.
3. Current enrollment in another clinical study, previous enrolment in this study, or previous use of any investigational or commercially available anti-HCV therapy (other than interferon, pegIFN, RBV, and or SOF) including previous exposure to telaprevir, boceprevir, ABT-450, or ombitasvir (ABT-267).
4. Subjects without cirrhosis: Any current or past clinical evidence of cirrhosis.
5. Abnormal lab tests.
6. Females who are pregnant or plan to become pregnant or breastfeeding, or males whose partners are pregnant or planning to become pregnant
Lipolytic Effects of GH in Human Subjects in Vivo

Growth hormone (GH) induces fat metabolism. The mechanisms underlying the fat metabolizing effects of GH remain elusive. However, it is known that insulin suppresses fat metabolism, and GH inhibits the expression of certain insulin-dependent signaling proteins. We therefore hypothesize that the fat metabolizing effects of GH depend on abrogation of insulin-dependent signaling pathways.

In order to investigate the fat metabolizing effects of GH, we'll analyze consecutive adipose tissue biopsies taken after GH exposure and GH blocking, respectively.

Knowledge of the effects of growth hormone and fat metabolism can in shot-sight as well as in long-sight have great importance for the understanding of growth disorders from overweight and type 2 diabetes to malnutrition and eating disorders.


Eligibility Criteria:
Inclusion Criteria:

* healthy males
* no medication
* BMI 28-35

Exclusion Criteria:

* known diseases
* regular medication